ArticleBrazilian journal of anesthesiology (Elsevier)2026
Efficacy and safety of ciprofol versus remimazolam combined with alfentanil for sedation during outpatient colonoscopy: a randomized double-blind noninferiority trial.
Article in Brazilian journal of anesthesiology (Elsevier), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionColonoscopy often causes significant discomfort to patients. To improve patient experience, sedation-assisted colonoscopy is being increasingly adopted. This study was designed to assess the efficacy and safety of ciprofol versus remimazolam combined with alfentanil during outpatient colonoscopy.
methodsA randomized, double-blind controlled clinical trial was performed among patients scheduled for elective outpatient colonoscopy. Patients were randomly allocated at a 1:1 ratio to two groups: the ciprofol group (Group C, 0.4 mg.kg
resultsIn the ITT population, colonoscopy success rates were 100.0% (88/88) in Group C and 98.9% (87/88) in Group R (treatment difference [95% CI]: 0.011 [-0.024 to 0.048]). The lower bound of the two-sided 95% CI was above the prespecified noninferiority margin of -0.08, confirming the noninferiority of ciprofol relative to remimazolam. After Bonferroni correction (adjusted threshold p < 0.0028), discharge time was longer in Group C (8.5 [6.0‒12.0] vs. 7.0 [5.0‒9.0] minutes; p = 0.002). Group R showed numerically higher MAP and HR at several time points.
conclusionsThis study demonstrated that intravenous ciprofol (0.4 mg.kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.